Publication: Factors associated with colistin-resistant acinetobacter baumannii acquisition among hospitalized patients
Issued Date
2018-08-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-85052239914
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.101, No.8 (2018), 1051-1054
Suggested Citation
Peerayuth Pantuwadeethorn, Amornrut Leelaporn, Pornpan Koomanachai Factors associated with colistin-resistant acinetobacter baumannii acquisition among hospitalized patients. Journal of the Medical Association of Thailand. Vol.101, No.8 (2018), 1051-1054. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46441
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Factors associated with colistin-resistant acinetobacter baumannii acquisition among hospitalized patients
Other Contributor(s)
Abstract
© 2018, Medical Association of Thailand. All rights reserved. Background: The emergence of multidrug-resistant Acinetobacter baumannii has led to the re-use of colistin. Colistin-resistant A. baumannii [CRA] was rare but is being reported more often now. Objective: To explore the factors associated with CRA. Materials and Methods: A retrospective case-control study has conducted. The medical records of 20 patients with CRA and 80 patients with colistin-susceptible A. baumannii [CSA] were reviewed. Results: Univariate analysis showed that presence of five co-morbidities, intensive care unit stay, prior use of colistin, duration of colistin use, and some prior antibiotics were associated with CRA (p<0.05). However, using multivariate analysis, prior colistin and meropenem use had adjusted odds ratios [AOR] of 21.04; 95% CI of 3.11 to 142.32 (p = 0.002) and 13.54; 95% CI of 1.15 to 159.64 (p = 0.038), respectively, for CRA. Colistin duration (days) was significantly associated with resistance (AOR 1.22, 95% CI of 1.04 to 1.44, p = 0.013). Conclusion: These results should increase awareness of appropriate colistin administration i.e., the duration of colistin used.